Greco F A, Richardson R L, Snell J D, Stroup S L, Oldham R K
Am J Med. 1979 Apr;66(4):625-30. doi: 10.1016/0002-9343(79)91173-2.
Thirty-two patients with limited-stage small cell lung cancer were treated with combined supervoltage radiotherapy and a combination of cyclophosphamide, doxorubicin and vincristine chemotherapy. The goal of obtaining a complete remission, the necessary step which precedes improved survival, was successful in 26 of 27 of completely re-evaluated patients. Fiberoptic bronchoscopy was useful in substantiating complete remission status. Seventeen of the 32 patients remain alive from 8+ to 28+ months (median 16+ months). Ten patients are alive and relapse-free from 12+ to 28+ months (median 19+ months). Transient granulocytopenia (mean nadir 650 cells/mm3) during induction therapy and the associated risk of infection were the most serious toxicities encountered. This therapy produces complete remission on roentgenography and bronchoscopy, symtomatic improvement and improved survival in the majority of patients with limited-stage small cell lung cancer. A portion of these patients may have their disease eradicated.
32例局限期小细胞肺癌患者接受了超高压放疗联合环磷酰胺、阿霉素和长春新碱化疗。在27例完全重新评估的患者中，有26例成功实现了完全缓解这一提高生存率之前的必要步骤。纤维支气管镜检查有助于证实完全缓解状态。32例患者中有17例存活了8个多月至28个多月（中位时间为16个多月）。10例患者存活且无复发，时间为12个多月至28个多月（中位时间为19个多月）。诱导治疗期间出现的短暂性粒细胞减少（平均最低点为650个细胞/mm³）以及相关的感染风险是所遇到的最严重毒性反应。这种治疗方法在大多数局限期小细胞肺癌患者中能使X线片和支气管镜检查显示完全缓解，症状改善且生存率提高。这些患者中有一部分可能已根除疾病。
